[go: up one dir, main page]

MX2020006071A - Nuevas formas solidas de cannabidiol y sus usos. - Google Patents

Nuevas formas solidas de cannabidiol y sus usos.

Info

Publication number
MX2020006071A
MX2020006071A MX2020006071A MX2020006071A MX2020006071A MX 2020006071 A MX2020006071 A MX 2020006071A MX 2020006071 A MX2020006071 A MX 2020006071A MX 2020006071 A MX2020006071 A MX 2020006071A MX 2020006071 A MX2020006071 A MX 2020006071A
Authority
MX
Mexico
Prior art keywords
cannabidiol
solid forms
new solid
cocrystals
proline
Prior art date
Application number
MX2020006071A
Other languages
English (en)
Inventor
Patricia Andres
Mark Andres
R Martin Emanuele
Tanise Shattock-Gordon
Tabitha Williford
Original Assignee
Artelo Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Artelo Biosciences Inc filed Critical Artelo Biosciences Inc
Publication of MX2020006071A publication Critical patent/MX2020006071A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
    • C07C39/23—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic, containing six-membered aromatic rings and other rings, with unsaturation outside the aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/12—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)

Abstract

En la presente se divulgan cocristales de cannabidiol y un coformador que contiene anillos de 5-6 miembros compuestos de átomos de carbono y nitrógeno, en donde los anillos de 5-6 miembros pueden ser insaturados o saturados y los anillos contienen 1 a 2 átomos de nitrógeno. También se divulgan en la presente los cocristales de cannabidiol y un coformador seleccionado de L-prolina, D-prolina, tetrametilpirazina y 4,4'-dipiridilo.
MX2020006071A 2017-12-11 2018-12-10 Nuevas formas solidas de cannabidiol y sus usos. MX2020006071A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762597307P 2017-12-11 2017-12-11
PCT/US2018/064773 WO2019118360A1 (en) 2017-12-11 2018-12-10 New solid forms of cannabidiol and uses thereof

Publications (1)

Publication Number Publication Date
MX2020006071A true MX2020006071A (es) 2020-10-28

Family

ID=66735157

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020006071A MX2020006071A (es) 2017-12-11 2018-12-10 Nuevas formas solidas de cannabidiol y sus usos.

Country Status (14)

Country Link
US (4) US20190177258A1 (es)
EP (1) EP3723752B1 (es)
JP (1) JP7429013B2 (es)
CN (1) CN111447929B (es)
AU (1) AU2018383598B2 (es)
BR (1) BR112020011625A2 (es)
CA (1) CA3085331A1 (es)
DK (1) DK3723752T3 (es)
ES (1) ES2992415T3 (es)
FI (1) FI3723752T3 (es)
MX (1) MX2020006071A (es)
PT (1) PT3723752T (es)
TW (1) TWI794361B (es)
WO (1) WO2019118360A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3107566A1 (en) * 2017-08-07 2019-02-14 Enantia, S.L. A cocrystal of 2-[(1r,6r)-6-isopropenyl-3-methylcyclohex-2-en-1-yl]-5-pentylbenzene-1,3-diol
US11667612B2 (en) * 2017-10-25 2023-06-06 Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for delivering pharmaceutical agents
EP3873459A1 (en) * 2018-10-31 2021-09-08 Enantia, S.L. Solid compositions of cocrystals of cannabinoids
GB201912760D0 (en) * 2019-09-05 2019-10-23 Healx Ltd Treatment
EP4025208A4 (en) * 2019-09-06 2023-12-06 Ebers Tech Inc. CANNABIGEROL PROLINE COCRYSTALS
US20230381134A1 (en) * 2020-01-03 2023-11-30 Purisys, Llc Cocrystals of cannabinoids
US10981849B1 (en) * 2020-02-20 2021-04-20 Sci Pharmtech Inc. Method for preparing cannabinoids
WO2021234449A1 (en) * 2020-05-19 2021-11-25 Ebers Tech Inc. Tetrahydrococannabinolic acid cocrystals
CN111882044B (zh) * 2020-08-05 2021-09-14 四川大学 一种基于图神经网络的共晶预测方法、深度学习框架
CA3198547A1 (en) 2020-11-16 2022-05-19 Mark RIDALL Rapidly infusing platform and compositions for therapeutic treatment in humans
US11672761B2 (en) 2020-11-16 2023-06-13 Orcosa Inc. Rapidly infusing platform and compositions for therapeutic treatment in humans
CN114177163B (zh) * 2022-01-12 2023-05-02 刘树民 一种治疗高血压的药物
WO2025122802A1 (en) * 2023-12-05 2025-06-12 Artelo Biosciences, Inc. Increased bioavailability and efficacy of cbd via coadministration with tetramethylpyrazine
US20250236581A1 (en) 2024-01-23 2025-07-24 Manoira Corporation Cannabidiolic acid cocrystals

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4859674A (en) 1987-06-12 1989-08-22 Houston Biotechnology Incorporated Pyrazine in prevention and treatment of strokes
EP1482917B1 (en) 2002-02-01 2019-05-08 GW Pharma Limited Compositions comprising cannabidiolic acid for treatment of nausea, vomiting, emesis, motion sickness or like conditions
GB2393182B (en) 2002-09-23 2007-03-14 Gw Pharma Ltd Method of preparing cannabidiol from plant material
EP1596869B1 (en) * 2003-01-21 2014-06-04 New Form Pharmaceuticals Inc. Novel cocrystallization
JP4923182B2 (ja) 2003-02-28 2012-04-25 マクニール−ピーピーシー・インコーポレーテツド セレコキシブ及びニコチンアミド共結晶並びにこの共結晶を含む医薬組成物
US7091205B2 (en) 2004-10-08 2006-08-15 Yu Show Fu Use of tetramethylpyrazine in the treatment of brain tumor
US8088773B2 (en) 2005-05-12 2012-01-03 The Texas A&M University System Therapeutic compositions and methods
TWI370818B (en) * 2006-04-05 2012-08-21 Astellas Pharma Inc Cocrystal of c-glycoside derivative and l-proline
CN101969955A (zh) 2008-01-31 2011-02-09 莫纳什大学 治疗血栓栓塞疾病的方法
EP2123626A1 (en) * 2008-05-21 2009-11-25 Laboratorios del Dr. Esteve S.A. Co-crystals of duloxetine and co-crystal formers for the treatment of pain
MX2011011445A (es) 2009-04-29 2011-11-18 Univ Kentucky Res Found Composiciones que contienen cannabinoides y metodos para su uso.
US8576985B2 (en) 2009-09-01 2013-11-05 Aptuit (West Lafayette) Llc Methods for indexing solid forms of compounds
US20110200531A1 (en) 2009-09-14 2011-08-18 The Regents Of The University Of California Treatment and diagnosis of central nervous system disorders
MX2012004782A (es) 2009-10-23 2012-09-12 Astellas Pharma Inc Composicion farmaceutica para administracion oral.
WO2012116349A2 (en) * 2011-02-26 2012-08-30 Amplio Pharma, Llc Novel cocrystals of ezetimibe
US20150224120A1 (en) 2011-09-14 2015-08-13 Catherine Clelland Compositions and methods for treating hyperprolinemia-associated mental disorders
WO2016010827A1 (en) 2014-07-14 2016-01-21 Librede Inc. Production of cannabinoids in yeast
EP3253727A4 (en) 2015-02-05 2018-08-08 Colorado Can LLC Purified cbd and cbda, and methods, compositions and products employing cbd or cbda
US10399920B2 (en) * 2016-06-01 2019-09-03 S&B Pharma, Inc. Crystalline form of cannabidiol
CA3107566A1 (en) * 2017-08-07 2019-02-14 Enantia, S.L. A cocrystal of 2-[(1r,6r)-6-isopropenyl-3-methylcyclohex-2-en-1-yl]-5-pentylbenzene-1,3-diol

Also Published As

Publication number Publication date
JP7429013B2 (ja) 2024-02-07
CA3085331A1 (en) 2019-06-20
US20210299048A1 (en) 2021-09-30
DK3723752T3 (da) 2024-11-04
CN111447929A (zh) 2020-07-24
TWI794361B (zh) 2023-03-01
EP3723752A1 (en) 2020-10-21
EP3723752B1 (en) 2024-08-21
BR112020011625A2 (pt) 2020-11-17
PT3723752T (pt) 2024-11-07
US20230404939A1 (en) 2023-12-21
US10604467B2 (en) 2020-03-31
WO2019118360A1 (en) 2019-06-20
KR20200097285A (ko) 2020-08-18
AU2018383598A1 (en) 2020-06-18
US11364202B2 (en) 2022-06-21
FI3723752T3 (fi) 2024-11-13
JP2021505674A (ja) 2021-02-18
TW201927733A (zh) 2019-07-16
ES2992415T3 (es) 2024-12-12
AU2018383598B2 (en) 2024-03-07
US20190177258A1 (en) 2019-06-13
CN111447929B (zh) 2024-05-31
EP3723752A4 (en) 2021-10-20
US20190300466A1 (en) 2019-10-03

Similar Documents

Publication Publication Date Title
MX2020006071A (es) Nuevas formas solidas de cannabidiol y sus usos.
MY186296A (en) Novel promoter and use thereof
MX2020006812A (es) Degradadores de cinasas asociadas al receptor de interleucina-1 (irak) y usos de los mismos.
PH12019550224A1 (en) Antitumoral compounds
SG10201805246XA (en) Approximated parameter adaptation
MX2019002453A (es) Compuestos de tetraciclina y metodos de uso de los mismos.
WO2017176957A8 (en) Mdm2 protein degraders
PH12019550235A1 (en) Kinase inhibitors and uses thereof
PH12015502702B1 (en) Fragrance composition
MX2020001793A (es) Inhibidores del receptor de hidrocarburos de arilo (ahr) y usos de los mismos.
ZA202309446B (en) Rapamycin analogs and uses thereof
SA519402288B1 (ar) مركب بيريميدين واستخداماته الصيدلانية
MX2019010950A (es) Composicion de fotosensibilizador que contiene fenalen-1-ona, compuesto de fenalen-1-ona, asi como su uso.
SA519410259B1 (ar) مركب كبير الحلقات واستخداماته
MX2020006596A (es) Hidroxiisoxazolinas y derivados de estos.
MX2020002435A (es) Agentes que modulan las funciones de beta-catenina y sus métodos.
MX2020012718A (es) Derivados de benzodiazepinas novedosos y usos de los mismos.
ZA201803476B (en) Anti-cd22 antibody-maytansine conjugates and methods of use thereof
SA520411726B1 (ar) مشتق فينيل بيريدين جديد وتركيبة صيدلانية تشتمل عليه
MY191114A (en) Methods, compositions and uses relating thereto
MX2020006434A (es) Nuevos compuestos inhibidores del blanco mecanistico de rapamicina (mtor).
SG11201903874VA (en) Umbrella
GEP20186893B (en) Pyrazines modulators of gpr6
WO2019109067A3 (en) Creatine prodrugs, compositions and methods of use thereof
MX2019013250A (es) 2,3,7-trimetiloct-6-enil acetato y 3,7-dimetil-2-metilen-oct-6-eni l acetato y derivados de estos y su uso como sustancias quimicas aromaticas.